Index by Company
(or go to index by date)
- Abbott Laboratories Announces European Approval of Uprima2001
- Abbott and Idun to Develop Apoptotic Cancer Drugs 1999
- Æterna: Phase I/II study results in prostate cancer confirm Neovastat's...2001
- Agouron Solves Structure of Key Target for Oncology: Checkpoint Kinase March 17, 2000
- Agouron - Warner-Lambert to Aquire Agouron Jan 26 99
- Alza Announces Approval of Viadur For Once-Yearly Palliative Treatment Of Advanced Prostate Cancer2000
- Amgen and Praecis Phase III Trial Results Announced...2001
- Amgen - Denosumab Osteoporosis Trial . . . Greater Gains in Bone Mineral Density versus Those Who Continued on Alendronate Sept 15 2008
- Amgen Submits Biologics License Application for FDA Approval of Denosumab in Women With Postmenopausal Osteoporosis and in Patients Undergoing Hormone Ablation for Either Prostate or Breast Cancer December 19, 2008
- Amgen Announces Positive Top-Line Results for Denosumab Treatment of Bone Loss in Men With Non-Metastatic Prostate Cancer Undergoing Androgen Deprivation Therapy July 14, 2008
- Aronex Study of ATRAGEN Jan 1999
- Aronex Pharmaceuticals Starts Clinical Trial of Atragen for Prostate Cancer 1998
- Bostwick Laboratories Announces uPM3(TM) Test, First Genetic Test for Prostate Cancer Sept 23,2003
- BioXell Initiates Phase IIb Trial of BXL628 in Benign Prostatic Hyperplasia Jul 2005
- Cell Pathways Scientists Describes Mechanism...2000
- Cell Pathways Says FDA Won't Approve Aptosyn for FAP at This Time2000
- Cell Therapeutics, Inc. Preliminary Clinical Results of XYOTAX(TM) Sept 24 2003
- Cougar Biotechnology Presents Positive CB7630 (Abiraterone Acetate) Phase I and Phase II Data at ASCO 2008 Annual Meeting June 2, 2008
- Cougar Biotechnology Announces Agreement with FDA on Special Protocol Assessment for Phase III trial of CB7630 (Abiraterone Acetate) April 1, 2008
- Cougar Biotechnology Presents CB7630 Phase I Data at Prostate Cancer Foundation Scientific Retreat Oct 25 2004
- CytoTherapeutics announces human brain stems purified from human tissue. 2000
- Phase III C-08 study of Avastin in early-stage colon cancer does not meet primary endpoint April 22 2009
- Cytogen Announces Positive Findings from Clinical Studies of QUADRAMET® in Prostate Cancer Patients with Metastatic Bone Disease Presented at ASCO Prostate Cancer Symposium Feb 27 2006
- Dendreon - PROVENGE Significantly Prolongs Survival in Men with Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study April 14, 2008
- Dendreon Announces New Data Analysis Presented at Chemotherapy Foundation Symposium Nov 10, 2006
- Dendreon Announces New Data Analyses Presented at Prostate Cancer Foundation Scientific Retreat Oct 20, 2006
- Provenge prostate cancer vaccine linked to longer survival for asymptomatic hormone refractory stage. June 28, 2006
- Dendreon Reports Preliminary D9902A Trial Data For Provenge in Patients With Advanced Prostate Cancer Jan. 11, 2005
- Dendreon Announces FDA Grants Fast Track Status for Provenge November 7, 2005
- Dendreon's Phase 3 Trial Shows Provenge Vaccine Extends Survival in Patients with Advanced Prostate Cancer Oct 28, 2004
- Dong-A PharmTech Co., Ltd. Announces Start of Phase III Trials for Udenafil, Its New Erectile Dysfunction Drug Under Development November 4, 2009
- Epigenomics Presents Data Confirming Screening for Methylated DNA in Blood as Key to Early Colorectal Cancer Detection April 3, 2006
- Endocare Announces Medicare Coverage for its Cryosurgery Procedure for Prostate Cancer Feb 16 1999
- Bristol Myers-Squibb and EntreMed Modify Research Agreement : Feb 10 1999
- Entremed, Inc. Signs Letter of Intent for GMP Production of Angiostatin Protein1999
- Etremed Signs Agreement with NCI to Study 2- Methoxyestradiol 1999
- Entremed Scientists Report Potent Angiogenic Effects in Preclinical Trials 1999
- EntreMed Low-Dose Cancer Therapy Featured at AACR Meeting
- Epigenomics' Biomarker in Prostate Cancer April 2006
- Epigenomics Presents Data Confirming Screening for Methylated DNA in Blood as Key to Early Colorectal Cancer Detection April 2006
-
Ferring -- FDA Approves Ferring Pharmaceuticals' Degarelix (Generic Name) for Treatment of Advanced Prostate Cancer Dec 24, 2008
- Genzyme gets $5 Million for p53 Gene Therapy European Patent February 5 1999
- Genzyme Licences Angiogenesis Inhibitor from Folkman Lab February 9 1999
- Genzyme and ATIII LLC Agree to Develop aaATIII as a Potential Cancer Therapy 1999
- Genzyme: Preclinical Study Cites Potency of aaATIII Discovered by Folkman, O'Reilly 1999
- GlaxoSmithKline and Adolor Present Positive Results From a Clinical Study of alvimopan (Entereg®) May 4, 2006
- NEW ANTI-ANGIOGENIC PROTEINS DISCOVERED 1999
- Illumina: Test using 16 Gene Profiles to Predict Prostate Cancer Relapse Looks Promising April 5, 2006
- Immunexs TRAIL Molecule Shows Potential as Anti-Tumor Agent 1999
- IMPATH Announces Venture with Physicians Network Jan 1999
- Meviation's MDV3100 Continues to Show Encouraging and Durable Anti-Tumor Activity and Dose Escalation Continues October 22, 2008
- Medarex MDX-210 in Trials for Prostate Cancer December 1998
- Mitotix Acquires License to p27 Gene June 1996
- Novacea Initiates Pivotal Phase 3 Clinical Study of DN-101 in Men With Advanced Prostate Cancer April 12 2006
- Novartis submits NDA for Zometa® (zoledronic acid for injection)
- Nycomed Amersham Imaging launches Website
- OncoGenex Announces In-Licensing and Development Plans for a Novel Cancer Therapeutic April-May 2005
- OncoGenex Technologies and Isis Pharmaceuticals Expand Antisense Drug Development Partnershp in Oncology March 2005
- Progenics and Cytogen Vaccine...at CaP CURE Retreat
- Proteome Systems & Egenix to Develop Semen-based prostate cancer test March 10, 2006
- Roberts Pharmaceutical LHRH One Year Implant Nearly Ready February 9 1999
- Roche -- Phase III C-08 study of Avastin in early-stage colon cancer does not meet primary endpoint April 22 2009
- SafeScience Accelerates Clinicals Studies of GBC-590 in Prostate and Pancreatic
Cancer Patients (June 1999) - TAP Pharmaceutical Products Inc. and Seven Others Charged With Health Care Crimes; Company Agrees To Pay $875 Million To Settle Charges, Reports U.S. Attorney. October 2001
- Tokai Pharmaceuticals Initiates ARMOR Clinical Development Program for TOK-001; First Ever Multi-Target Investigational Drug for Prostate Cancer November 12, 2009
